Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | KDM1B | Q8NB78 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 6/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 4/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.46 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7095292 | 1.00 | KDM1A (0.48) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL8146309 | 1.00 | KDM1A (0.48) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL7004268 | 1.00 | KDM1A (0.48) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL4508197 | 0.82 | SLC6A4 (0.41) | KDM1AKDM1BSLC6A2SLC6A3 | |
| SCHEMBL7089683 | 0.82 | CYP3A4 (0.45) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL7001619 | 0.82 | CYP3A4 (0.45) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL8134479 | 0.82 | CYP3A4 (0.45) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL7001620 | 0.82 | CYP3A4 (0.45) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL7003893 | 0.82 | KCNH2 (0.45) | KDM1AKCNH2KDM1BMAOBRCOR1 | |
| SCHEMBL7003889 | 0.82 | KCNH2 (0.45) | KDM1AKCNH2KDM1BMAOBRCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688568-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9346840-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8853408-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2688568-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-01-29 | — | — | EP | disclosed |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Glaxo Smith Kline LLC | 2014-01-16 | — | — | US | disclosed |
| WO-2012135113-A2 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-10-04 | — | — | WO | disclosed |
| EP-0996621-B1 | TRIAZOLO[4,5-d]PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS | ASTRAZENECA AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| US-6251910-B1 | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists | ASTRAZENECA UK LIMITED (GB) | 2001-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM3B | KDM1A 2/4885KCNH2 2006/4885KDM1B 1/4885 |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885KCNH2 2006/4885KDM1B 1/4885 |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885KCNH2 2006/4885KDM1B 1/4885 |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885KCNH2 2006/4885KDM1B 1/4885 |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM1A 2/4885KCNH2 2006/4885KDM1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.